

Marina Magrey

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5516087/publications.pdf>

Version: 2024-02-01

31
papers

1,550
citations

566801

15
h-index

525886

27
g-index

31
all docs

31
docs citations

31
times ranked

2045
citing authors

#	ARTICLE	IF	CITATIONS
1	2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. <i>Arthritis and Rheumatology</i> , 2017, 69, 1521-1537.	2.9	399
2	2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2019, 71, 5-32.	2.9	312
3	Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis. <i>New England Journal of Medicine</i> , 2021, 384, 1227-1239.	13.9	143
4	Efficacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with non-radiographic axial spondyloarthritis (ABILITY-3): a multicentre, randomised, double-blind study. <i>Lancet</i> , 2018, 392, 134-144.	6.3	81
5	New insights into synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome. <i>Current Rheumatology Reports</i> , 2009, 11, 329-333.	2.1	78
6	A unifying biologic explanation for high-sensitivity C-reactive protein and low-grade inflammation. <i>Arthritis Care and Research</i> , 2010, 62, 442-446.	1.5	64
7	Prevalence and distribution of peripheral musculoskeletal manifestations in spondyloarthritis including psoriatic arthritis: results of the worldwide, cross-sectional ASAS-PerSpA study. <i>RMD Open</i> , 2021, 7, e001450.	1.8	64
8	Osteoporosis in Ankylosing Spondylitis. <i>Current Rheumatology Reports</i> , 2010, 12, 332-336.	2.1	60
9	Anti-glomerular basement membrane antibody disease treated with rituximab: A case-based review. <i>Seminars in Arthritis and Rheumatism</i> , 2013, 42, 567-572.	1.6	53
10	Screening and Treatment of Osteoporosis After Hip Fracture: Comparison of Sex and Race. <i>Journal of Clinical Densitometry</i> , 2014, 17, 479-483.	0.5	49
11	Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study. <i>RMD Open</i> , 2021, 7, e001838.	1.8	42
12	Recognizing Axial Spondyloarthritis: A Guide for Primary Care. <i>Mayo Clinic Proceedings</i> , 2020, 95, 2499-2508.	1.4	31
13	Utility of DXA scanning and risk factors for osteoporosis in ankylosing spondylitis—A prospective study. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 46, 88-94.	1.6	27
14	Sacroiliitis mimics: a case report and review of the literature. <i>BMC Musculoskeletal Disorders</i> , 2017, 18, 170.	0.8	26
15	Clinical Manifestations and Diagnosis of Axial Spondyloarthritis. <i>Journal of Clinical Rheumatology</i> , 2021, 27, e547-e560.	0.5	24
16	Clinical utility, safety, and efficacy of pregabalin in the treatment of fibromyalgia. <i>Drug, Healthcare and Patient Safety</i> , 2016, 8, 13.	1.0	17
17	Effect of tofacitinib on pain, fatigue, health-related quality of life and work productivity in patients with active ankylosing spondylitis: results from a phase III, randomised, double-blind, placebo-controlled trial. <i>RMD Open</i> , 2022, 8, e002253.	1.8	14
18	Primary Sjogren's syndrome with anticentromere antibodies—a clinically distinct subset. <i>Clinical Rheumatology</i> , 2010, 29, 789-791.	1.0	11

#	ARTICLE	IF	CITATIONS
19	Worldwide Differences in Clinical Phenotype of Axial Spondyloarthritis. <i>Current Rheumatology Reports</i> , 2021, 23, 76.	2.1	10
20	Measuring outcomes in ankylosing spondylitis: pearls and pitfalls. <i>Current Opinion in Rheumatology</i> , 2019, 31, 109-117.	2.0	9
21	Understanding Barriers in the Pathway to Diagnosis of Ankylosing Spondylitis: Results From a US Survey of 1690 Physicians From 10 Specialties. <i>ACR Open Rheumatology</i> , 2020, 2, 616-626.	0.9	7
22	Malignancy in ankylosing spondylitis: a cross-sectional analysis of a large population database. <i>BMC Rheumatology</i> , 2022, 6, .	0.6	7
23	Evaluation of the Feasibility of a Web-Based Survey to Assess Patient-Reported Symptom Improvement and Treatment Satisfaction Among Patients with Psoriatic Arthritis Receiving Secukinumab. <i>Clinical Drug Investigation</i> , 2019, 39, 1205-1212.	1.1	5
24	A Pilot Study to Assess the Feasibility of a Web-Based Survey to Examine Patient-Reported Symptoms and Satisfaction in Patients with Ankylosing Spondylitis Receiving Secukinumab. <i>Drugs - Real World Outcomes</i> , 2019, 6, 83-91.	0.7	5
25	Identification of clinical phenotypes of peripheral involvement in patients with spondyloarthritis, including psoriatic arthritis: a cluster analysis in the worldwide ASAS-PerSpA study. <i>RMD Open</i> , 2021, 7, e001728.	1.8	5
26	Use of upadacitinib in the treatment of psoriatic arthritis. <i>Immunotherapy</i> , 2021, 13, 1549-1554.	1.0	4
27	Pain in Axial Spondyloarthritis: More to It Than Just Inflammation. <i>Journal of Rheumatology</i> , 2021, 48, 1632-1634.	1.0	3
28	HLA-B27 Homozygosity and Clinical Features of Ankylosing Spondylitis. <i>Current Rheumatology Reports</i> , 2010, 12, 309-310.	2.1	0
29	P178â€fThe impact of peripheral articular manifestations on the efficacy of ixekizumab in patients with radiographic axial spondyloarthritis. <i>Rheumatology</i> , 2021, 60, .	0.9	0
30	P173â€fEfficacy and safety of upadacitinib versus placebo and adalimumab in patients with active PsA and inadequate response to non-biologic DMARDs (SELECT-PSA-1): a double-blind, randomised controlled phase III trial. <i>Rheumatology</i> , 2021, 60, .	0.9	0
31	Nonradiographic axial spondyloarthritis: expanding the spectrum of an old disease. <i>Medicine (United Tj ETQq1 1 0,784314 rgBT /Ove</i>	0,4	8